Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Checkpoint kinase 1 (Chk1) inhibitors are investigated as monotherapy and chemotherapy potentiators.
• Understanding the tumor growth environment's effect on Chk1 signaling is crucial for clinical translation.

Purpose of the Study:

• To investigate how tumor microenvironment factors influence Chk1 signaling and sensitivity to Chk1 inhibition.
• To explore correlations between replication proteins, Chk1/Cdc6 expression, and drug sensitivity.

Main Methods:

• Utilized spheroid and low-serum culture models to mimic tumor growth conditions.
• Analyzed Chk1 signaling, DNA damage response (DDR), and protein expression (Cdc6, Chk1).
• Correlated protein expression with sensitivity to Chk1 inhibitors in vitro and analyzed human cancer databases.

Main Results:

• Spheroid culture mimicked xenograft Chk1 signaling but reduced sensitivity to Chk1 inhibition.
• Low-serum conditions increased tumor cell sensitivity to Chk1 inhibition without altering DDR signaling.
• Observed correlations between Cdc6 and Chk1/pChk1 in xenograft and anchorage-dependent samples.
• Found no direct correlation between Chk1/Cdc6 expression and in vitro sensitivity to Chk1 inhibitors.
• Database analysis showed CDC6 upregulation in tumors and correlation with CHEK1 mRNA expression in human cancers.

Conclusions:

• Tumor microenvironment significantly modulates Chk1 signaling and drug response.
• Cdc6 overexpression in human tumors may necessitate increased Chk1 to manage DNA damage from origin hyperactivation.
• Chk1 inhibitors' efficacy may depend on specific tumor microenvironment contexts.